Mounjaro Weight Loss Results: What to Expect in the UK

What the Clinical Trials Show

The SURMOUNT clinical trial programme provides the most robust data on Mounjaro weight loss outcomes. In the SURMOUNT-1 trial, participants who completed 72 weeks (approximately 18 months) of treatment achieved the following average weight loss results: 5mg dose — approximately 15% of body weight, 10mg dose — approximately 19.5% of body weight, 15mg dose — approximately 22.5% of body weight.

For context, a person weighing 100kg (15 stone 10 lbs) could expect to lose approximately 15-22.5kg (2.4 to 3.5 stone) over 18 months depending on their maintenance dose. These are averages — individual results varied significantly, with some participants losing considerably more.

Month-by-Month Weight Loss Timeline

Month 1 (2.5mg): Most patients lose 1-3kg during the starter dose phase. This is primarily due to reduced appetite rather than the full pharmacological effect, as 2.5mg is a sub-therapeutic dose designed to help your body adjust.

Months 2-3 (5mg): Weight loss typically accelerates to 1-2kg per week. Appetite suppression becomes more noticeable, and many patients report significant changes in their relationship with food.

Months 3-6 (7.5mg-10mg): This is often the most dramatic phase of weight loss. Patients commonly lose 5-10kg during this period as the medication reaches more effective dose levels.

Months 6-12 (10mg-15mg): Weight loss continues but the rate gradually slows. Most patients are approaching their maintenance dose and seeing steady, sustainable progress.

Months 12-18: Weight loss plateaus for many patients as they reach a new stable weight. This is normal and expected — the focus shifts to weight maintenance.

Factors That Affect Your Results

Several factors influence how much weight you will lose on Mounjaro. Starting weight and BMI — patients with a higher starting BMI tend to lose a greater absolute amount of weight. Dose — higher maintenance doses are associated with greater weight loss in clinical trials. Diet and exercise — while Mounjaro reduces appetite significantly, patients who also make dietary improvements and increase physical activity tend to see better results. Adherence — taking your injection consistently every week at the same time maximises effectiveness. Individual metabolism — genetic and metabolic factors mean some people respond more strongly to GLP-1/GIP medications than others.

It is worth noting that approximately 5-10% of patients in clinical trials were classified as 'non-responders' who lost less than 5% of body weight. If you have not lost at least 5% after 3-4 months on an adequate dose, discuss alternative options with your prescriber.

Mounjaro vs Wegovy: Weight Loss Comparison

Head-to-head data from clinical trials shows that Mounjaro produces significantly greater weight loss than Wegovy (semaglutide). At comparable timepoints, Mounjaro 15mg achieved approximately 22.5% body weight loss versus 14-17% for Wegovy 2.4mg. This difference is attributed to Mounjaro's dual mechanism — it activates both GIP and GLP-1 receptors, while Wegovy targets only GLP-1.

In terms of cost-effectiveness, Mounjaro and Wegovy are similarly priced in the UK private market (£120-£340 per month). However, Mounjaro's greater efficacy means patients may achieve their weight loss goals sooner, potentially reducing the total cost of treatment.

How to Maximise Your Results

Based on clinical evidence and UK patient experiences, here are strategies to get the most from your Mounjaro treatment. Follow the prescribed dose escalation schedule without skipping or rushing. Take your injection on the same day each week at a consistent time. Focus on protein-rich meals to preserve muscle mass during weight loss. Incorporate resistance training 2-3 times per week — this is crucial for maintaining muscle and metabolic rate. Stay well hydrated with at least 2 litres of water daily. Track your progress with measurements and photos, not just the scale — body composition changes may not always show on the scales. Be patient during plateaus — they are normal and temporary.

What Happens When You Stop Mounjaro?

Clinical trial data shows that patients who discontinue Mounjaro tend to regain approximately two-thirds of the weight they lost within 12 months of stopping. This is consistent with the understanding that obesity is a chronic condition requiring ongoing management.

For this reason, many patients and prescribers view Mounjaro as a long-term treatment rather than a short-term fix. The cost implications of long-term treatment make pharmacy price comparison especially important — saving £50 per month adds up to £600 per year. Some patients transition to a lower maintenance dose to reduce costs while maintaining some of the medication's appetite-suppressing effects.